 |
|
|
|
|
Washington Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2022 replacing WashingtonLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
ARCH Venture Partners
| | | | | Phone: | (206) 674-3028 | | Fax: | (206) 674-3026 | | Year Established: | 1996 | | Employees: | 7 | | Main Contact: | Robert Nelsen, Managing Director | | | | Company Description | | ARCH Venture Partners is a premier provider of seed and early stage venture capital for the commercialization of innovations in life sciences, information technology and the physical sciences. The partnership’s special expertise is to found, co-found, and build technology firms from startup. Partnering with entrepreneurs, academic institutions and national research laboratories nationwide, ARCH has built more than 90 successful companies, many of them from the concept stage. ARCH’s biotechnology investments include founding round or first round investments in Caliper Technologies (CALP), Illumina Inc. (ILMN), decode genetics, Inc. (DCGN), Array BioPharma (ARRY), Genomica (GNOM), Aviron (AVIR), Adolor Corporation (ADLR), GenVec, IDUN Pharmaceuticals, Surface Logix, Xcyte Therapies, Inc., CEPTYR, Inc., Xenoport, Elixir Pharmaceuticals and Nanosys. ARCH manages over $700 million. | |
|
|
|
|
|
|
|
